About

Jakko A. Nieuwenhuijzen is a leading urologic oncologist whose research centers on improving the staging and surgical management of prostate cancer, particularly through the integration of advanced molecular imaging. His major contributions lie in validating the clinical utility of PSMA PET/CT, especially the 18F-DCFPyL tracer, for detecting pelvic lymph-node metastases. His landmark SALT trial (106 citations) demonstrated the superior accuracy of PSMA PET/CT over conventional imaging for nodal staging, while the DeTeCT trial (47 citations) explored its potential for guiding targeted biopsies. Nieuwenhuijzen has also developed and externally validated a novel nomogram (35 citations) that combines MRI and PSMA PET data to predict lymph-node involvement, offering a powerful tool for clinical decision-making. Beyond diagnostics, his work includes refining surgical techniques for urinary continence reconstruction in robot-assisted radical prostatectomy and investigating focal laser ablation. His research consistently shows high impact, with multiple papers exceeding 20 citations, and has directly influenced how clinicians stage prostate cancer, potentially sparing many patients from unnecessary extended pelvic lymph-node dissections.

Research Focus

Key Achievements

10
H-Index
24
Papers
431
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
106 citations · 2020
📈 Most Prolific Year: 2021 (5 Papers)
🤝 Key Collaborators: 164
🏛 Institutions: Amsterdam UMC Location VUmc, Amsterdam University Medical Centers, The Netherlands Cancer Institute, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago